Document Detail

Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction.
MedLine Citation:
PMID:  12717099     Owner:  NLM     Status:  MEDLINE    
Allopurinol, an inhibitor of xanthine oxidase, was shown to improve the regional ventricular function after coronary artery occlusion and reperfusion in animal models. The effects of oral administration of allopurinol on a transient increase in free radical generation after primary percutaneous transluminal coronary angioplasty (PTCA) in patients with acute myocardial infarction (AMI) and on their clinical outcomes were examined. Thirty-eight AMI patients undergoing primary PTCA were randomly assigned to control (group 1, n = 20) and allopurinol treatment groups (group 2, n = 18). Allopurinol (400 mg) was administered orally just after the admission (approximately 60 min before reperfusion). Free radical production was assessed by successive measurement of urinary excretion of 8-epi-prostaglandin F(2alpha) (PGF(2alpha)) after PTCA. Urinary 8-epi-PGF(2alpha) excretion was increased by twofold at 60-90 min after PTCA compared with the baseline value in group 1. This increase was completely inhibited in group 2. Plasma allopurinol concentration was 1,146 +/- 55 ng/ml in group 2 when reperfusion was achieved. Slow flow in the recanalized coronary artery after PTCA occurred less frequently in group 2 than in group 1. Cardiac index determined just after reperfusion and left ventricular ejection fraction at 6 months after PTCA were both significantly greater in group 2 than in group 1 although pulmonary capillary wedge pressure was similar in the two groups. In conclusion, allopurinol pretreatment is effective in inhibiting generation of oxygen-derived radicals during reperfusion therapy and the recovery of left ventricular function in humans.
Weiping Guan; Tomohiro Osanai; Takaatsu Kamada; Hiroyuki Hanada; Hiroshi Ishizaka; Hiroyuki Onodera; Atsushi Iwasa; Norio Fujita; Shigeaki Kudo; Tadashi Ohkubo; Ken Okumura
Related Documents :
2956849 - Late angiographic follow-up after successful coronary arterial thrombolysis and angiopl...
17703159 - Evaluation of stentangioplasty in university cardiac center.
11100389 - Technical achievement: transthoracic doppler echocardiography can be used to detect lad...
7586249 - A comparison of the costs of and quality of life after coronary angioplasty or coronary...
10806989 - Evaluation of ischemia-reperfusion damage during coronary angioplasty. electrocardiogra...
2947689 - Risk of preangioplasty occlusion and myocardial infarction in one-vessel-disease patien...
7831179 - Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses...
16355919 - Bnp as a biomarker in heart disease.
19077819 - Re-evaluating risk factors for periprocedural complications during percutaneous coronar...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  41     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-04-28     Completed Date:  2004-03-18     Revised Date:  2004-12-03    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  699-705     Citation Subset:  IM    
Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Allopurinol / administration & dosage,  blood,  therapeutic use*
Angioplasty, Transluminal, Percutaneous Coronary*
Dinoprost* / analogs & derivatives*
F2-Isoprostanes / urine
Free Radical Scavengers / administration & dosage,  blood,  therapeutic use*
Free Radicals / metabolism
Middle Aged
Myocardial Infarction / complications,  metabolism,  therapy*
Myocardial Reperfusion Injury / drug therapy,  etiology,  metabolism
Oxypurinol / blood
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/F2-Isoprostanes; 0/Free Radical Scavengers; 0/Free Radicals; 2465-59-0/Oxypurinol; 27415-26-5/8-epi-prostaglandin F2alpha; 315-30-0/Allopurinol; 551-11-1/Dinoprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Na+/H+ exchange inhibition with cardioplegia reduces cytosolic [Ca2+] and myocardial damage after co...
Next Document:  Effects of two beta3-agonists, CGP 12177A and BRL 37344, on coronary flow and contractility in isola...